Highlights Cytokinetics, Incorporated

Equities

CYTK

US23282W6057

Market Closed - Nasdaq Other stock markets 21:00:00 07/05/2024 BST			5-day change	1st Jan Change
65.28 ^USD	+0.35%		+6.46%	-21.81%

05-07	Cytokinetics Insider Sold Shares Worth $1,012,265, According to a Recent SEC Filing	MT
04-26	Cytokinetics Appoints Sung Lee as CFO	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Rise Friday Afternoon	04-05	MT
Cytokinetics Reports Positive Follow-On Data for Prospective Heart Medication; Shares Rise	04-05	MT
Cytokinetics Presents Additional 48-Week Data from Forest-Hcm, the Open Label Extension Clinical Study of Aficamten, At the American College of Cardiology 73rd Annual Scientific Session	04-05	CI
Cytokinetics Q4 Net Loss Narrows, Revenue Decreases; 2024 Outlook Issued	02-27	MT
Earnings Flash (CYTK) CYTOKINETICS INCORPORATED Reports Q4 Revenue $1.7M, vs. Street Est of $13.3M	02-27	MT
Cytokinetics, Incorporated Provides Revenue Guidance for 2024	02-27	CI
Cytokinetics, Incorporated Reports Earnings Results for the Full Year Ended December 31, 2023	02-27	CI
Cytokinetics, Incorporated Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-27	CI
Novartis Interest in Cytokinetics Takeover Has Cooled	01-11	MT
Correction: Market Chatter: Novartis Interest in Cytokinetics Takeover Has Cooled	01-11	MT
Cytokinetics Shares Slide as Novartis Reportedly Shies Away From Deal	01-11	DJ
Novartis drops pursuit of Cytokinetics - WSJ	01-11	RE
Novartis Pursuit of Cytokinetics Reportedly Cools	01-10	CI
Cytokinetics Shares Jump 16% After WSJ Report of Novartis Deal	01-08	DJ
Novartis Reportedly in Advanced Talks to Buy Cytokinetics, Deal Possible This Week	01-08	MT
Novartis in advanced talks to buy Cytokinetics- WSJ	01-08	RE
Novartis Reportedly in Advanced Talks to Buy Cytokinetics	01-08	CI
Cytokinetics heart drug succeeds in closely watched study, shares surge	12-27	RE
Cytokinetics' heart disease drug meets main goal in study	12-27	RE
Cytokinetics, Incorporated Announces Positive Results from Sequoia-Hcm, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy	12-27	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cytokinetics, Incorporated

Equities

CYTK

US23282W6057

Highlights

Filters